Evidence of efficacy: CBD and Parkinson's

enfleur-blog-parkinsons-effective-cbd.png
ENFLEUR 1000mg Broad Spectrum Cannabinoids
Quick View
ENFLEUR 1000mg Broad Spectrum Cannabinoids
65.00
Quantity:
Add To Cart
ENFLEUR 1000mg Full Spectrum Cannabinoids
Quick View
ENFLEUR 1000mg Full Spectrum Cannabinoids
65.00
Quantity:
Add To Cart

ENFLEUR is pleased to share a very encouraging 2018 review of clinical and pre-clinical studies published by Frontiers in Pharmacology, a rigorously peer-reviewed journal, suggesting that CBD plays both a therapeutic and preventative role in Parkinson’s. The review includes data from human studies indicating that CBD decreases the psychotic symptoms associated with Parkinson’s, reduced the frequency of events related to Parkinson’s sleep behavior disorders, and after six weeks of treatment, improved Parkinson’s patients’ quality of life likely through CBD’s anti-anxiety, antidepressant, and antipsychotic properties. CBD was also found to act preventatively in terms of dystonia in Parkinson’s. It was also noted that, in rodent trials, CBD has been shown to prevent and/or reverse catalepsy behavior associated with Parkinson’s. Studies in animal models of Parkinson’s also showed that CBD had a neuroprotective effect, which is significant as Parkinson’s is a neurodegenerative disease. This review also affirms that studies report that CBD does not impair cognitive function, and in fact is able to improve it in some conditions.

Over time, Parkinson’s disease is a significantly debilitating condition. The potential for a potent, high caliber CBD product to improve quality of life and offer neuroprotection is a hopeful discovery for those living with Parkinson’s.

Why does this matter? Studies show CBD’s has emerged as a promising compound in the treatment and/or prevention of many symptoms associated with Parkinson’s.